荣灿生物 focuses on the development and industrialization of gene (nucleic acid) therapeutics and related services. The company aims to be a full‑chain nucleic acid business covering sequence design, mRNA raw material synthesis, delivery vector synthesis, and final drug development. Its core offerings span nucleic acid sequence design, synthesis of mRNA raw materials, and synthesis of delivery vectors. The company recently completed an A round financing of over RMB 100 million, recorded via an industrial registration change. Proceeds are intended to accelerate product research and development and to support team building. Management plans to use the funds to advance its leading pipeline toward clinical research. Founded in June 2020, Rongcan Biotech operates an end‑to‑end mRNA and LNP R&D and pilot production platform, including GMP‑compatible pilot lines (~4,000 m²) to support IND and clinical I–II sample production. The company has built an independent IP portfolio around novel cationic lipid structures and formulations, and its founders hold a U.S. patent for a new cationic lipid carrier jointly developed with Professor Robert Langer (founder listed as first inventor). Rongcan reports peer‑reviewed results from its delivery technology in top journals (Science Translational Medicine, Nature Biomedical Engineering, PNAS, Science Advances) and has screened 5,000+ LNPs in vivo. Preclinical head‑to‑head studies reportedly show its LNPs match or outperform leading international competitors on delivery efficiency, safety, cost, and stability, with low‑temperature storage advantages. The company has achieved liver‑external targeting breakthroughs (atherosclerotic plaque and lung targeting) and developed an inhalable lung delivery system, demonstrating therapeutic effects in animal models. Rongcan is collaborating with domestic vaccine firms and research institutes and was selected as one of eight major key projects in the National Biopharmaceutical Technology Innovation Center "揭榜挂帅" initiative.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2023